VIRUS AND OTHER INFECTION-ASSOCIATED CANCERS RESEARCH PROGRAM PROGRAM CODE: VOIC PROJECT SUMMARY/ABSTRACT The Virus and Other Infection-associated Cancer (VOIC) Research Program explores associations between microbial infections and human cancer and accelerates clinical applications of basic science findings. The program brings together 27 outstanding investigators from four different schools focused on cancer-associated microbial pathogens, immunology, and translational and implementation science. The previously designated ?Molecular Virology? research program was most recently ranked Outstanding to Exceptional, with strong research in nearly all human tumor viruses. In recognition of the emerging and important role of bacteria in tumorigenesis, the program name was changed from ?Molecular Virology? to ?Virus and Other Infection- associated Cancers? (VOIC). In the current funding period, VOIC program accomplishments include improved understanding of underlying causal relationships between microbial infections and human cancer that has provided new mechanism-based insights for therapeutic and preventive cancer interventions, including vaccines. The link between microbial infections and cancer is well established for seven human tumor viruses that cause up to ~15% of all human cancer. Nine program members study human tumor viruses, contributing fundamental insights into latency, cell growth, and carcinogenesis. Current research also focuses on a better understanding of the role of human papillomaviruses (HPV) in oropharyngeal cancer, as well as immune responses to viral infections?research that will assist with the development of effective vaccines. Since emergence of the HIV/AIDS pandemic and its associated cancers, the VOIC program has aimed to understand basic mechanisms of HIV infection, pathogenesis, and immune modulation to develop strategies to decrease the significant cancer burden associated with HIV. VOIC has been at the forefront in defining a shift in cancers from classic AIDS-defining cancers to non?AIDS-defining cancers in aging patients on long-term antiretroviral therapy (ART). Nine program members work at the interface of HIV/AIDS and cancer, performing both basic and translational research towards a cure and a vaccine, as well as advancing clinical trials. Bacterial associations with human cancer have been frequently observed in gastric cancer, colorectal cancer, and gallbladder cancer, but causal relationships are less well understood. To foster research in this important area, five program members were recruited to VOIC to study the human microbiome and cancer and translate microbiome research from mouse to human disease. In addition, the Yale Cancer Center (YCC) funded two pilot grants in the microbiome and cancer, and established a microbiome biobank for colorectal-cancer patients that will be a valuable resource for basic and translational research. VOIC members published 333 cancer- related papers (July 1, 2012-June 1, 2017) of which 11% were intraprogrammatic and 23% interprogrammatic. VOIC cancer research funding totals $10.3M (direct) of which $9.4M is peer reviewed, a 24% increase in peer-reviewed funding relative to the last submission in 2012.!

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-41
Application #
9989602
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053

Showing the most recent 10 out of 675 publications